Payment overview · 2025
General Payments
$231.78
12 reported records · 8 companies
Healthcare provider profile · identity verified
Jeffrey Wayne Long, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HALEYVILLE, AL · NPI 1245326933
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Wayne Long, D.O. received $231.78 in general payments during 2025 across 12 reported records.
Supernus Pharmaceuticals, Inc. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.51 | 33.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.97 | 15.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.08 | 15.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.37 | 8.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.71 | 8.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.48 | 7.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.06 | 6.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.60 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $231.78 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $78.51 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $35.08 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 477 | 134 |
| Gabapentin | Gabapentin | 471 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 435 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 386 | 119 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 348 | 56 |
| Omeprazole | Omeprazole | 337 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 109 |
| Meloxicam | Meloxicam | 289 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 289 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 96 |
| Metformin Hcl | Metformin Hcl | 268 | 87 |
| Montelukast Sodium | Montelukast Sodium | 253 | 73 |
| Furosemide | Furosemide | 251 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 70 |
| Famotidine | Famotidine | 226 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 63 |
| Losartan Potassium | Losartan Potassium | 210 | 60 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 201 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 196 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 55 |
| Trazodone Hcl | Trazodone Hcl | 178 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 47 |
| Azithromycin | Azithromycin | 161 | 123 |
| Cefdinir | Cefdinir | 145 | 111 |
| Tramadol Hcl | Tramadol Hcl | 121 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 120 | 30 |
| Allopurinol | Allopurinol | 118 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 42 |
| Simvastatin | Simvastatin | 109 | 36 |
| Pregabalin | Pregabalin | 108 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 49 |
| Potassium Chloride | Potassium Chloride | 105 | 38 |
| Eliquis | Apixaban | 100 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 98 | 36 |
| Lorazepam | Lorazepam | 97 | 18 |
| Clonazepam | Clonazepam | 96 | 14 |
| Ondansetron Odt | Ondansetron | 96 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 28 |
| Januvia | Sitagliptin Phosphate | 83 | 20 |
| Buspirone Hcl | Buspirone Hcl | 82 | 23 |
| Topiramate | Topiramate | 82 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | suppressed |
| Carvedilol | Carvedilol | 79 | 30 |
| Ozempic | Semaglutide | 79 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 17 |
| Farxiga | Dapagliflozin Propanediol | 70 | 16 |
| Sertraline Hcl | Sertraline Hcl | 70 | 24 |
| Jardiance | Empagliflozin | 69 | 16 |
| Cephalexin | Cephalexin | 66 | 51 |
| Amoxicillin | Amoxicillin | 65 | 47 |
| Clonidine Hcl | Clonidine Hcl | 64 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 22 |
| Fluconazole | Fluconazole | 63 | 36 |
| Linzess | Linaclotide | 63 | 20 |
| Atenolol | Atenolol | 57 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 18 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 14 |
| Glimepiride | Glimepiride | 53 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 17 |
| Mupirocin | Mupirocin | 52 | 43 |
| Methylprednisolone | Methylprednisolone | 51 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 11 |
| Prednisone | Prednisone | 45 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Etodolac | Etodolac | 43 | 24 |
| Spironolactone | Spironolactone | 43 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 14 |
| Lidocaine | Lidocaine | 42 | 14 |
| Meclizine Hcl | Meclizine Hcl | 42 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 39 | 15 |
| Lansoprazole | Lansoprazole | 39 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 11 |
| Glipizide | Glipizide | 37 | 11 |
| Methocarbamol | Methocarbamol | 37 | 16 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Lovastatin | Lovastatin | 35 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 29 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 27 |
| Rexulti | Brexpiprazole | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 27 |
| Celecoxib | Celecoxib | 30 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 16 |
| Valacyclovir | Valacyclovir Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 14 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Nitroglycerin | Nitroglycerin | 20 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 15 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nystatin | Nystatin | 15 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $231.78 · 12 records | Supernus Pharmaceuticals, Inc. | BREZTRI, CREON, FANAPT, JOURNAVX, Korlym, LINZESS, NEXLETOL, Ozempic, QULIPTA, Qelbree, UBRELVY, VIBERZI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error